Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Conditions: Bladder Cancer; Urothelial Carcinoma; Transitional Cell Carcinoma; Platinum-Resistant Urothelial Carcinoma; Bladder Urothelial Carcinoma; FGFR Mutation; FGFR2 Gene Mutation; FGFR3 Gene Mutation; FGFR2 Amplification; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Refractory Bladder Carcinoma; Refractory Bladder Urothelial Carcinoma
Intervention: Drug: Balversa
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
September 23, 2021 /
/ in Oncology